BioCryst Pharmaceuticals Stock Forecast
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BCRX analyst consensus
Consensus (11 analysts)
buy
Avg. price target
$20.73+150.06%
- Strong buy 2
- Buy 7
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering BioCryst Pharmaceuticals (2026-10-07), 9 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $20.73, with a high estimate of $32.00 and a low estimate of $11.00. The average target implies upside of 150.1% from the current price of $8.29.
The spread between the highest and lowest targets is 190.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BCRX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 18% |
| Buy | 7 | 64% |
| Hold | 2 | 18% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $11.00 | +32.69% |
| Average target | $20.73 | +150.06% |
| High target | $32.00 | +286.01% |